DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panels (SEP): Control of Plague in Uganda, Program Announcement (PA) Number CI 06–007

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Control of Plague in Uganda, PA Number CI 06–007.

Time and Date: 12 p.m.–4 p.m., May 3, 2006 (Closed).

Place: Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to: Control of Plague in Uganda, Program Announcement Number CI 06–007.

For Further Information Contact: Christine Morrison, PhD, Scientific Review Administrator, Office of Extramural Research, CDC, 1600 Clifton Road, NE, Mailstop D–72, Atlanta, GA 30333, Telephone Number 404–639–3098.

Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control, Special Emphasis Panel (SEP): Impact of DRG 559 on Costs, Quality and Patient Outcomes of Stroke Care, Program Announcement Number PEP 2006–R–07

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Disease, Disability, and Injury Prevention and Control, Special Emphasis Panel (SEP): Impact of DRG 559 on Costs, Quality and Patient Outcomes of Stroke Care, Program Announcement Number PEP 2006–R–07.

Time and Date: 1 p.m.–2 p.m., May 18, 2006 (Closed).

Place: Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters to be Discussed: To conduct expert review of scientific and technical merit of research applications in response to Impact of DRG 559 on Costs, Quality and Patient Outcomes of Stroke Care, Program Announcement Number PEP 2006–R–07.

For Further Information Contact: Felix Rogers, Ph.D., M.P.H., Scientific Review Administrator, CDC, 1600 Clifton Road NE, Mailstop E05, Atlanta, GA 30333, Telephone 404–639–6101.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.


Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E6–5171 Filed 4–7–06; 8:45 am]

BILLING CODE 4163–18–P
anthropometry that are to be used in computer simulation?

(4) What are the essential cab accommodation models to be developed once updated anthropometric and workspace data become available?

The public is invited to attend and will have the opportunity to provide comments. NIOSH will use this information to assess the scientific basis for the current pilot project and the possible large-scale project on U.S. truck driver anthropometric and workspace data.

Status: The consortium meeting will include scientists and representatives from various government agencies, industry and other stakeholders and is open to the public, limited only by the space available. The meeting room accommodates 40 people. Due to limited space, notification of intent to attend the meeting must be made to Jinhua Guan, PhD, not later than April 14, 2006. Dr. Guan can be reached by telephone at (304) 599–4676 or by e-mail at egg6@cdc.gov. Requests to attend the meeting will be accommodated on a first-come basis.

Non-U.S. Citizens: Because of CDC Security Regulations, non-U.S. citizens wishing to attend this meeting must provide the following information in writing to Barbara Phillips (telephone: 304–285–6325; fax: (304) 285–6039; e-mail: djp2@cdc.gov) no later than April 14, 2006:
1. Visitor’s Full Name:
2. Gender:
3. Date of Birth:
4. Place of Birth (city, province, state, country):
5. Citizenship:
6. Passport Number:
7. Date of Passport Issue:
8. Date of Passport Expiration:
9. Type of Visa:
10. Visitor’s Organization:
11. Organization Address:
12. Organization Telephone Number:
13. Visitor’s Position/Title within the Organization:

This information will be transmitted to the CDC Security Office for approval. Visitors will be notified as soon as approval has been obtained.

A copy of the research protocol titled “NIOSH Pilot Study of Truck Driver Anthropometric and Workspace Dimensions” can be obtained from the CDC Internet at http://www.cdc.gov/niosh/docs/ or a hard copy may be requested from the Docket Officer, Karen Dragon (see contact information below).

**ADDRESSES:** Comments should be submitted to the NIOSH Docket Office, ATTN: Karen Dragon, Robert A. Taft Laboratories, 4676 Columbia Parkway, M/S C–34, Cincinnati, Ohio 45226, telephone 513/533–8303, fax 513/533–8285.

Comments may also be submitted directly through the Web site (http://www.cdc.gov/niosh/docs/) or by e-mail to: nicindocket@cdc.gov. E-mail attachments should be formatted in Microsoft Word. Comments should be submitted to NIOSH no later than June 30, 2006, and should reference docket number NIOSH–068 in the subject heading.

Oral comments made at the public meeting must also be submitted to the docket office in writing in order to be considered by the Agency.

All information received in response to this notice will be available for public examination and copying at the NIOSH Docket Office, Room 111, 4676 Columbia Parkway, Cincinnati, Ohio 45226.

**Contact Person for Technical Information:** Jinhua Guan, PhD, telephone (304) 285–6333, Division of Safety Research, NIOSH, 1095 Willowdale Road, Morgantown, WV 26505.


James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.

For further information contact:
Jonna Capezzuto, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4659.

**SUPPLEMENTARY INFORMATION:** In the Federal Register of December 22, 2005 (70 FR 76056), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0578. The approval expires on March 31, 2009. A copy of the supporting statement for this information collection is available on the Internet at http://www.fda.gov/ohrms/dockets.


Jeffrey Shuren,
Assistant Commissioner for Policy.

[FR Doc. E6–5142 Filed 4–7–06; 8:45 am]

**BILLING CODE** 4160–01–S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. 2005N–0327]**

**Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Blood Establishment Registration and Product Listing, Form FDA 2830**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a collection of information entitled “Blood Establishment Registration and Product Listing, Form FDA 2830” has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

**FOR FURTHER INFORMATION CONTACT:** Jonna Capezzuto, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4659.

**SUPPLEMENTARY INFORMATION:** In the Federal Register of January 25, 2006 (71 FR 4145), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the